Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The Evolution of GLP-1RA Usage GLP-1RA drugs have been used in clinical practice since the mid-2000s
The SURMOUNT trial program involved large, diverse populations
Lipid Profile Improvements Retatrutide produced favorable changes in multiple lipid parameters: Non-HDL cholesterol: Clinically meaningful reduction Triglycerides: Substantial decrease Total cholesterol: Improved levels Inflammatory Markers High-sensitivity C-reactive protein (hs-CRP), a key marker of systemic inflammation and cardiovascular risk, showed clinically meaningful reductions with retatrutide treatment
Each of these receptors plays a distinct role in metabolic regulation, and the combination represents a meaningful step beyond the dual agonism of tirzepatide, which targets only GLP-1R and GIPR
Retatrutide doses are increased every 4 weeks based on tolerance
US$ 27.02
US$ 25.71
US$ 24.66
US$ 28.12
US$ 21.69
US$ 25.49
US$ 29.52
